Immune C2, C3, and C6 had higher abundance of B cell and DC1, CD8A, CD8B, and hub genes (Figure 10B), which indicated that immune C2, C3, and C6 lung cancer patients were suitable for immunotherapy and would benefit more from ICB therapy. This evidence concerns the gene CD8A and lung cancer.